Aerie Pharmaceuticals to Participate in the H.C. Wainwright Ophthalmology Conference

Rhea-AI Summary

Aerie Pharmaceuticals (NASDAQ: AERI) announced that Dr. Casey C. Kopczynski, Chief Scientific Officer, will participate in a virtual panel discussion at the H.C. Wainwright Ophthalmology Conference. This event, titled “What are the Greatest Unmet Needs Facing Ophthalmology Today?”, is scheduled for August 17, 2021, at 9:00 a.m. Eastern Time. Interested attendees can access the live webcast via Aerie's website, with a replay available for 10 business days.

Aerie specializes in ophthalmic therapies for conditions like open-angle glaucoma and ocular surface diseases.

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Casey C. Kopczynski, Ph.D., Chief Scientific Officer, will participate in a virtual panel discussion titled, “What are the Greatest Unmet Needs Facing Ophthalmology Today?”, at the H.C. Wainwright Ophthalmology Conference. The panel will be held on Tuesday, August 17, 2021 at 9:00 a.m. Eastern Time.

The panel discussion will be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com. A replay of the panel discussion will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa^® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa^®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan^® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa^® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan^®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005040/en/

FAQ

What is the date and time of Aerie Pharmaceuticals' virtual panel discussion?

The virtual panel discussion is scheduled for August 17, 2021, at 9:00 a.m. Eastern Time.

Who is participating in the H.C. Wainwright Ophthalmology Conference on behalf of Aerie Pharmaceuticals?

Dr. Casey C. Kopczynski, Chief Scientific Officer, will participate in the panel discussion.

What is the topic of the Aerie Pharmaceuticals panel discussion?

The panel discussion is titled “What are the Greatest Unmet Needs Facing Ophthalmology Today?”.

Where can I watch the Aerie Pharmaceuticals panel discussion?

You can watch the panel discussion live on Aerie Pharmaceuticals' website.

Will the panel discussion by Aerie Pharmaceuticals be available for replay?

Yes, a replay of the panel discussion will be available for 10 business days after the event.